2025
Pain Management in the Older Adults A Narrative Review
Rajput K, Ng J, Zwolinski N, Chow R. Pain Management in the Older Adults A Narrative Review. Clinics In Geriatric Medicine 2025, 41: 131-151. PMID: 39551538, DOI: 10.1016/j.cger.2024.03.011.Peer-Reviewed Original ResearchConceptsPain managementOlder adult populationOlder adult patientsOlder adultsAdult populationMultiple medicationsLife expectancyClinical practiceAdult patientsMedical managementPreexisting comorbiditiesPainUnited StatesDegenerative processPracticeNonagenariansMedicationAdultsComorbiditiesReviewManagementOctogenariansPatients
2023
Pain Management in the Elderly A Narrative Review
Rajput K, Ng J, Zwolinski N, Chow R. Pain Management in the Elderly A Narrative Review. Anesthesiology Clinics 2023, 41: 671-691. PMID: 37516502, DOI: 10.1016/j.anclin.2023.03.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsClinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review
Weleff J, Kovacevich A, Burson J, Nero N, Anand A. Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review. Journal Of Addiction Medicine 2023, 17: 407-417. PMID: 37579098, DOI: 10.1097/adm.0000000000001141.Peer-Reviewed Original ResearchConceptsWithdrawal casesClinical presentationConcomitant substance useLength of hospital stayAverage length of hospital staySystematic treatment protocolCochrane Library databasesAtypical antipsychoticsComprehensive literature searchSubstance useAddictive agentHospital stayPublished casesBenzodiazepinesPhenibutLibrary databasesToxicity casesAntipsychoticsTreatment protocolsPsychosisWithdrawalMultiple medicationsAverage ageMental statusMovement disorders
2022
Polypharmacy Among People Living with Dementia — Israel and 24 Countries in European Union, 2015–2019
Chen S, Chen X, Zhang H. Polypharmacy Among People Living with Dementia — Israel and 24 Countries in European Union, 2015–2019. China CDC Weekly 2022, 4: 1007-1012. PMID: 36483007, PMCID: PMC9709303, DOI: 10.46234/ccdcw2022.204.Peer-Reviewed Original Research
2020
Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis
Kaplan DE, Serper M, John BV, Tessiatore KM, Lerer R, Mehta R, Fox R, Aytaman A, Baytarian M, Hunt K, Albrecht J, Taddei TH, Group V. Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. Clinical Gastroenterology And Hepatology 2020, 19: 2148-2160.e14. PMID: 32798709, DOI: 10.1016/j.cgh.2020.08.026.Peer-Reviewed Original ResearchConceptsDiagnosis of cirrhosisEnzyme inhibitors/angiotensinMetformin exposureHepatic decompensationHepatocellular carcinomaDiabetes mellitusPrognosis of cirrhosisPropensity-matched approachPre-existing diabetesRetrospective cohort studyLarge national cohortVeterans Health AdministrationMarginal structural modelsConcomitant statinCohort studyMultiple medicationsStatin exposureNational cohortCirrhosisPatientsDiabetesDecompensationMetforminConcomitant exposureHealth Administration
2019
Efficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis.
Dobson ET, Bloch MH, Strawn JR. Efficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis. The Journal Of Clinical Psychiatry 2019, 80 PMID: 30753760, DOI: 10.4088/jcp.17r12064.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsTolerability of pharmacotherapyTreatment-emergent suicidalityMedication classesTreatment responsePediatric anxiety disordersAnxiety disordersReuptake inhibitorsTolerability of medicationsPlacebo-controlled trialSerotonin reuptake inhibitorsNetwork Meta-AnalysisRisk of biasWeb of ScienceCause discontinuationGeMTC packageSuicidality dataCochrane riskMultiple medicationsBias toolPediatric patientsMedication trialsAgonist treatmentCochrane Database
2018
Depressive Symptoms Are Associated With Low Treatment Adherence in African American Individuals With Systemic Lupus Erythematosus
Heiman E, Lim S, Bao G, Drenkard C. Depressive Symptoms Are Associated With Low Treatment Adherence in African American Individuals With Systemic Lupus Erythematosus. JCR Journal Of Clinical Rheumatology 2018, 24: 368-374. PMID: 29912774, PMCID: PMC6487191, DOI: 10.1097/rhu.0000000000000794.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusLow medication adherencePopulation-based cohortMedication adherenceDepressive symptomsLow adherenceLupus erythematosusFemale sexYounger ageHigher disease activity scoresMorisky Medication Adherence ScaleLogistic regressionDisease Activity ScoreLow treatment adherenceMedication Adherence ScalePatient Health QuestionnaireSevere depressive symptomsSignificant risk factorsPatient-physician communicationUnivariate logistic regressionAA individualsPhysician communication styleMental health interventionsLupus CohortMultiple medicationsLevodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease
Manza P, Schwartz G, Masson M, Kann S, Volkow ND, Li CR, Leung HC. Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease. Neurobiology Of Aging 2018, 66: 12-22. PMID: 29501966, PMCID: PMC6436810, DOI: 10.1016/j.neurobiolaging.2018.02.003.Peer-Reviewed Original ResearchConceptsEarly-stage Parkinson's diseaseParkinson's diseaseDopaminergic medicationAdvanced Parkinson's diseaseStriatal activationResponse inhibitionRole of dopaminergicAge-matched controlsFunctional magnetic resonance imagingMagnetic resonance imagingExecutive functionLevodopa monotherapyMultiple medicationsMotor symptomsSignificant group differencesPD groupStop-signal taskAdvanced stageLevodopaResonance imagingMedicationsFunctional connectivityCritical executive functionMotor inhibitionPatients
2016
Barriers to participation in industry‐sponsored clinical trials in pediatric type 2 diabetes
Farrell R, Bethin K, Klingensmith G, Tamborlane WV, Gubitosi‐Klug R. Barriers to participation in industry‐sponsored clinical trials in pediatric type 2 diabetes. Pediatric Diabetes 2016, 18: 574-578. PMID: 27807915, DOI: 10.1111/pedi.12465.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAttitude of Health PersonnelChildDiabetes Mellitus, Type 2Drug ApprovalDrug IndustryDrugs, InvestigationalEndocrinologyHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInternetNeeds AssessmentPatient SelectionPediatricsRandomized Controlled Trials as TopicResearch PersonnelResearch Support as TopicSocieties, ScientificSurveys and QuestionnairesUnited StatesUnited States Food and Drug AdministrationWorkforceConceptsPediatric Endocrine SocietyType 2 diabetesClinical trialsPediatric endocrinologistsIndustry-sponsored clinical trialsPatients age 18 yearsPediatric type 2 diabetesCurrent glycemic controlNew T2D casesAdditional treatment optionsAge 18 yearsBaseline demographicsT2D patientsGlycemic controlMedication useMultiple medicationsPediatric patientsResearch nursesPediatric populationTreatment optionsEndocrine SocietyT2D casesDrug AdministrationVisit scheduleAnonymous online survey
2010
Medication Effects on Sleep
Roux FJ, Kryger MH. Medication Effects on Sleep. Clinics In Chest Medicine 2010, 31: 397-405. PMID: 20488296, DOI: 10.1016/j.ccm.2010.02.008.Chapters
2009
Evidence‐Based Recommendations for the Assessment and Management of Sleep Disorders in Older Persons
Bloom HG, Ahmed I, Alessi CA, Ancoli‐Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC. Evidence‐Based Recommendations for the Assessment and Management of Sleep Disorders in Older Persons. Journal Of The American Geriatrics Society 2009, 57: 761-789. PMID: 19484833, PMCID: PMC2748127, DOI: 10.1111/j.1532-5415.2009.02220.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSpecific sleep disordersSleep disordersExpert-based recommendationsOlder personsRestless legs syndromeCircadian rhythm sleep disordersEvidence-based recommendationsSleep-related disordersPatient care practicesSerious medical problemTerm care settingsOlder adult populationMultiple medicationsPsychosocial comorbiditiesLegs syndromeSleep apneaCerebrovascular diseaseStrong bidirectional relationshipCardiovascular diseaseHigh prevalenceCare settingsSleep problemsHigh riskAmbulatory settingCare practices
2008
Cumulative Anticholinergic Exposure Is Associated with Poor Memory and Executive Function in Older Men
Han L, Agostini JV, Allore HG. Cumulative Anticholinergic Exposure Is Associated with Poor Memory and Executive Function in Older Men. Journal Of The American Geriatrics Society 2008, 56: 2203-2210. PMID: 19093918, PMCID: PMC3952110, DOI: 10.1111/j.1532-5415.2008.02009.x.Peer-Reviewed Original ResearchConceptsTotal anticholinergic burdenCumulative anticholinergic exposureOlder menAnticholinergic medicationsAnticholinergic burdenAnticholinergic exposureCumulative exposureVeterans Affairs primary care clinicsExecutive functionAnticholinergic medication useDeleterious adverse effectsProspective cohort studySeverity of hypertensionCommunity-dwelling menPrimary care clinicsDaily Living ScalePotential risk factorsPrescription of drugsAnticholinergic scoreCohort studyMultiple medicationsAnticholinergic effectsMedication useCare clinicsPhysical function
2005
The Complexity and Cost of Drug Regimens of Older Patients Hospitalized With Heart Failure in the United States, 1998-2001
Masoudi FA, Baillie CA, Wang Y, Bradford WD, Steiner JF, Havranek EP, Foody JM, Krumholz HM. The Complexity and Cost of Drug Regimens of Older Patients Hospitalized With Heart Failure in the United States, 1998-2001. JAMA Internal Medicine 2005, 165: 2069-2076. PMID: 16216996, DOI: 10.1001/archinte.165.18.2069.Peer-Reviewed Original ResearchConceptsHeart failureOlder patientsNumber of drugsDrug regimensComplex drug regimensPatients 65 yearsChronic lung diseaseNumber of dosesPrior revascularizationConcurrent prescriptionsMultiple comorbiditiesChronic medicationsElderly patientsHospital dischargeMultiple medicationsMedical therapyLung diseaseMultivariable modelDrug treatmentWhite raceMore drugsPatientsYounger ageDrugsUtilization measures
2002
Chemical Gastropathy: A Distinct Histopathologic Entity in Children
Pashankar D, Bishop W, Mitros F. Chemical Gastropathy: A Distinct Histopathologic Entity in Children. Journal Of Pediatric Gastroenterology And Nutrition 2002, 35: 653-657. DOI: 10.1002/j.1536-4801.2002.tb07923.x.Peer-Reviewed Original ResearchNonsteroidal anti-inflammatory drugsChemical gastropathyAntral biopsy specimensAnti-inflammatory drugsSmooth muscle fibersFoveolar hyperplasiaMultiple medicationsBiopsy specimensHistopathologic entityLamina propria edemaCommon presenting symptomGastroesophageal reflux diseaseAbsence of inflammationMuscle fibersStandard diagnostic criteriaGastric antral mucosaDistinct histopathologic entityAntral histologyEpigastric painReactive gastritisPresenting symptomReflux diseaseEndoscopic findingsAcid suppressionClinical course
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply